In vitro gene expression analysis of hepatotoxic drugs in rat primary hepatocytes

Journal of Applied Toxicology

Volumn 28, Issue 2, 2008, Pages 227-236

  Suzuki, Hiromi ^a   Inoue, Tomoaki ^a   Matsushita, Tomochika ^a   Kobayashi, Kazuko ^a   Horii, Ikuo ^b   Hirabayashi, Yoko ^c   Inoue, Tohru ^c  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Gene expression; Hepatotoxicity; In vitro; Microarray; Primary culture

Indexed keywords

CHLORPROMAZINE; CISPLATIN; CLOFIBRATE; CYCLOPHOSPHAMIDE; DICLOFENAC; DISULFIRAM; LITHOCHOLIC ACID; PARACETAMOL;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; GENE CLUSTER; GENE EXPRESSION; GENETIC TRANSCRIPTION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL;

ACETAMINOPHEN; ANIMALS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CLOFIBRATE; CLUSTER ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; GENE EXPRESSION PROFILING; HEPATOCYTES; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TIME FACTORS; TOXICITY TESTS; TRANSCRIPTION, GENETIC;

RATTUS;

EID: 41149164258     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1328     Document Type: Article

References (49)

1. Akerboom T, Schneider I, vom Dahl S, Sies H. 1991. Cholestasis and changes of portal pressure caused by chlorpromazine in the perfused rat liver. Hepatology 13: 216-221.
2. Baker VA, Harries HM, Waring JF, Duggan CM, Ni HA, Jolly RA, Yoon LW, De Souza AT, Schmid JE, Brown RH, Ulrich RG, Rockett JC. 2004. Clofibrate-induced gene expression changes in rat liver: a cross-laboratory analysis using membrane cDNA arrays. Environ. Health Perspect. 112: 428-438.
3. Boelsterli UA. 2003. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol. 192: 307-322.
4. Cantoni L, Valaperta R, Ponsoda X, Castell JV, Barelli D, Rizzardini M, Mangolini A, Hauri L, Villa P. 2003. Induction of hepatic heme oxygenase-1 by diclofenac in rodents: role of oxidative stress and cytochrome P-450 activity. J. Hepatol. 38: 776-783.
5. Carey MC, Hirom PC, Small DM. 1976. A study of the physicochemical interactions between biliary lipids and chlorpromazine hydrochloride. Bile-salt precipitation as a mechanism of phenothiazine-induced bile secretory failure. Biochem. J. 153: 519-531.
6. Cavalli F, Tschopp L, Sonntag RW, Zimmermann A. 1978. A case of liver toxicity following cis-dichlorodiammineplatinum(II) treatment. Cancer Treat. Rep. 62: 2125-2126.
7. Chen C, Hennig GE, Whiteley HE, Manautou JE. 2002. Protection against acetaminophen hepatotoxicity by Clofibrate pretreatment: role of catalase induction. J. Biochem. Mol. Toxicol. 16: 227-234.
8. Chu G. 1994. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J. Biol. Chem. 269: 787-790.
9. de Longueville F, Atienzar FA, Marcq L, Dufrane S, Evrard S, Wouters L, Leroux F, Bertholet V, Gerin B, Whomsley R, Arnould T, Remacle J, Canning M. 2003. Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytes. Toxicol. Sci. 75: 378-392.
10. DeLeve LD. 1996. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 24: 830-837.
11. Elias E, Boyer JL. 1979. Chlorpromazine and its metabolites alter polymerization and gelation of actin. Science 206: 1404-1406.
12. Eliasson E, Stal P, Oksanen A, Lytton S. 1998. Expression of autoantibodies to specific cytochromes P450 in a case of disulfiram hepatitis. J. Hepatol. 29: 819-825.
13. Esterbauer H, Schaur RJ, Zollner H. 1991. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11: 81-128.
14. Forns X, Caballeria J, Bruguera M, Salmeron JM, Vilella A, Mas A, Pares A, Rodes J. 1994. Disulfiram-induced hepatitis. Report of four cases and review of the literature. J. Hepatol. 21: 853-857.
15. Heinloth AN, Irwin RD, Boorman GA, Nettesheim P, Fannin RD, Sieber SO, Snell ML, Tucker CJ, Li L, Travlos GS, Vansant G, Blackshear PE, Tennant RW, Cunningham ML, Paules RS. 2004. Gene expression profiling of rat livers reveals indicators of potential adverse effects. Toxicol. Sci. 80: 193-202.
16. Huang Q, Dunn RT, 2nd, Jayadev S, DiSorbo O, Pack FD, Fair SB, Stoll RE, Blanchard KT. 2001. Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol. Sci. 63: 196-207.
17. Huang Q, Jin X, Gaillard ET, Knight BL, Pack FD, Stoltz JH, Jayadev S, Blanchard KT. 2004. Gene expression profiling reveals multiple toxicity endpoints induced by hepatotoxicants. Mutat. Res. 549: 147-167.
18. Kakis G, Phillips MJ, Yousef IM. 1980. The respective roles of membrane cholesterol and of sodium potassium adenosine triphosphatase in the pathogenesis of lithocholate-induced cholestasis. Lab. Invest. 43: 73-81.
19. Kakis G, Yousef IM. 1978. Pathogenesis of lithocholate- and taurolithocholate-induced intrahepatic cholestasis in rats. Gastroenterology 75: 595-607.
20. Klaassen CD (ed.). 2004. Casarett & Doull's Toxicology, 6th edn. McGraw-Hill Companies, Inc., Japanese translation through UNI Agency Tokyo; 968.
21. Klaunig JE, Goldblatt PJ, Hinton DE, Lipsky MM, Chacko J, Trump BF. 1981. Mouse liver cell culture. I. Hepatocyte isolation. In Vitro 17: 913-925.
22. Kretz-Rommel A, Boelsterli UA. 1993. Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes. Toxicol. Appl. Pharmacol. 120: 155-161.
23. Lee WM. 2003. Drug-induced hepatotoxicity. N. Engl. J. Med. 349: 474-485.
24. Leuschner U, Czygan P, Liersch M, Frohling W, Stiehl A. 1977. [Morphologic studies on the toxicity of sulfated and nonsulfated lithocholic acid in the isolation-perfused rat liver]. Z. Gastroenterol. 15: 246-253.
25. Li YQ, Prentice DA, Howard ML, Mashford ML, Desmond PV. 2000. Bilirubin and bile acids may modulate their own metabolism via regulating uridine diphosphate-glucuronosyltransferase expression in the rat. J. Gastroenterol. Hepatol. 15: 865-870.
26. Liu J, Liu Y, Habeebu SS, Klaassen CD. 1998. Metallothionein (MT)-null mice are sensitive to cisplatin-induced hepatotoxicity. Toxicol. Appl. Pharmacol. 149: 24-31.
27. Manautou JE, Hoivik DJ, Tveit A, Hart SG, Khairallah EA, Cohen SD. 1994. Clofibrate pretreatment diminishes acetaminophen's selective covalent binding and hepatotoxicity. Toxicol. Appl. Pharmacol. 129: 252-263.
28. Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brodie BB. 1973. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J. Pharmacol. Exp. Ther. 187: 211-217.
29. Miyai K, Richardson AL, Mayr W, Javitt NB. 1977. Subcellular pathology of rat liver in cholestasis and choleresis induced by bile salts. 1. Effects of lithocholic, 3beta-hydroxy-5-cholenoic, cholic, and dehydrocholic acids. Lab. Invest. 36: 249-258.
30. Miyamoto G, Zahid N, Uetrecht JP. 1997. Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. Chem. Res. Toxicol. 10: 414-419.
31. Morishita K, Mizukawa Y, Kasahara T, Okuyama M, Takashima K, Toritsuka N, Miyagishima T, Nagao T, Urushidani T. 2006. Gene expression profile in liver of differing ages of rats after single oral administration of acetaminophen. J. Toxicol. Sei. 31: 491-507.
32. Murray M. 1992. Inhibition and induction of cytochrome P450 2B1 in rat liver by promazine and chlorpromazine. Biochem. Pharmacol. 44: 1219-1222.
33. Nicholls-Grzemski FA, Calder IC, Priestly BG. 1992. Peroxisome proliferators protect against paracetamol hepatotoxicity in mice. Biochem. Pharmacol. 43: 1395-1396.
34. Nicholls-Grzemski FA, Calder IC, Priestly BG, Burcham PC. 2000. Clofibrate-induced in vitro hepatoprotection against acetaminophen is not due to altered glutathione homeostasis. Toxicol. Sci. 56: 220-228.
35. Patterson TA, Lobenhofer EK, Fulmer-Smentek SB, Collins PJ, Chu TM, Bao W, Fang H, Kawasaki ES, Hager J, Tikhonova IR, Walker SJ, Zhang L, Hurban P, de Longueville F, Friscoe JC, Tong W, Shi L, Wolfinger RD. 2006. Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat. Biotechnol. 24: 1140-1150.
36. Peters JM, Aoyama T, Cattley RC, Nobumitsu U, Hashimoto T, Gonzalez FJ. 1998. Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver. Carcinogenesis 19: 1989-1994.
37. Pumford NR, Myers TG, Davila JC, Highet RJ, Pohl LR. 1993. Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac. Chem. Res. Toxicol. 6: 147-150.
38. Qu B, Li QT, Wong KP, Tan TM, Halliwell B. 2001. Mechanism of Clofibrate hepatotoxicity: mitochondrial damage and oxidative stress in hepatocytes. Free Radic. Biol. Med. 31: 659-669.
39. Ray SD, Balasubramanian G, Bagchi D, Reddy CS. 2001. Ca(2+)-calmodulin antagonist chlorpromazine and poly(ADP-ribose) polymerase modulators 4-aminobenzamide and nicotinamide influence hepatic expression of BCL-XL and P53 and protect against acetaminophen-induced programmed and unprogrammed cell death in mice. Free Radic. Biol. Med. 31: 277-291.
40. Rizzardini M, Ferraroli A, Dal Fiume D, Cantoni L. 1984. Cyclophosphamide-impaired regulation of hepatic heme metabolism. Experientia 40: 1390-1392.
41. Romano A, Pietrantonio F, Di Fonso M, Garcovich A, Chiarelli C, Venuti A, Barone C. 1994. Positivity of patch tests in cutaneous reaction to diclofenac. Two case reports. Allergy 49: 57-59.
42. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantser A, Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A, Trush V, Quackenbush J. 2003. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34: 374-378.
43. Salama A, Gottsche B, Mueller-Eckhardt C. 1991. Autoantibodies and drug- or metabolite-dependent antibodies in patients with diclofenac-induced immune haemolysis. Br. J. Haematol. 77: 546-549.
44. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, et al. 2006. The MicroArray Quality Control (MAQC) project shows inter-and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24: 1151-1161.
45. Tavoloni N, Reed JS, Hruban Z, Boyer JL. 1979. Effect of chlorpromazine on hepatic perfusion and bile secretory function in the isolated perfused rat liver. J. Lab. Clin. Med. 94: 726-741.
46. Tien ES, Davis JW, Vanden Heuvel JP. 2004. Identification of the CREB-binding protein/p300-interacting protein CITED2 as a peroxisome proliferator-activated receptor alpha coregulator. J. Biol. Chem. 279: 24053-24063.
47. Wang K, Shindoh H, lnoue T, Horii I. 2002. Advantages of in vitro cytotoxicity testing by using primary rat hepatocytes in comparison with established cell lines. J. Toxicol. Sci. 27: 229-237.
48. Xie H, Afsharian P, Terelius Y, Mirghani RA, Yasar U, Hagbjork AL, Lundgren S, Hu Y, Rane A, Hassan M. 2005. Cyclophosphamide induces mRNA, protein and enzyme activity of cytochrome P450 in rat. Xenobiotica 35: 239-251.
49. Yu J, Lo JL, Huang L, Zhao A, Metzger E, Adams A, Meinke PT, Wright SD, Cui J. 2002. Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J. Biol. Chem. 277: 31441-31447.